-
Email to friend
-
Print
-
Add This
-
RSS Feed
- Font size: A A A
BMY | Quote | Chart | News | PowerRating -- Tranzyme Pharma, a biopharmaceutical company in Durham, has entered into a multi-million dollar collaboration with drug company Bristol-Myers Squibb Co. to develop novel bioactive macrocycles.
The macrocycles are a new compound class with the high potency and selectivity of large biomolecules and the oral availability and low cost of small molecule drugs, according to the companies.
Under terms of the agreement, Tranzyme will be primarily responsible for early lead discovery, and Bristol-Myers will complete preclinical and clinical development of all products arising from the collaboration, and for their commercialization globally.
Bristol-Myers will provide an upfront payment of $10 million and an additional $3 million to $6 million in research funding to Tranzyme for an initial two-year term. Tranzyme will receive further funding if the agreement is extended and be eligible to receive development and regulatory milestones and tiered royalties for each product resulting from the collaboration.
Total milestone payments under the agreement, excluding royalties, could reach up to approximately $80 million for each target program.
-- From staff reports
To see more of The Herald-Sun, or to subscribe to the newspaper, go to
http://www.herald-sun.com. Copyright (c) 2009, The Herald-Sun, Durham, N.C.
Distributed by McClatchy-Tribune Information Services. For reprints, email
tmsreprints@permissionsgroup.com, call 800-374-7985 or 847-635-6550, send a fax
to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave.,
Suite 303, Glenview, IL 60025, USA.
For full details on Bristol-Myers Squibb Co (BMY) BMY. Bristol-Myers Squibb Co (BMY) has Short Term PowerRatings at TradingMarkets. Details on Bristol-Myers Squibb Co (BMY) Short Term PowerRatings is available at This Link.
Do you want to learn how to trade more successfully, more consistently... and with more confidence?
If so, then the TPS strategy is for you.
Hundreds, if not now thousands, of ETF traders successfully use the TPS trading strategy to find the best ETF trade set-ups each day to place winning trades.
What stocks and ETFs are headed up and down this week?.
The TradingMarkets Weekly Newsletter covers this in depth and gives performance information on the previous week.
| Name | Symbol | PR |
| PowerShares DB US Dollar Bullish Fund | UUP | 10 |
| iPath S&P 500 VIX Mid-Term Futures ETN | VXZ | 10 |
| ProShares UltraShort MSCI Brazil | BZQ | 9 |
| PowerShares DB Gold Double Long Exchange Traded Note | DGP | 9 |
| Direxion Developed Markets Bear 3X Shares | DPK | 9 |
| ProShares UltraShort MSCI EAFE | EFU | 9 |
| ProShares Trust II: UltraShort Euro | EUO | 9 |
| SPDR Gold Shares | GLD | 9 |
| iShares COMEX Gold Trust | IAU | 9 |
| Powerwave Technologies | PWAV | 9 |
